Weight-losing patients with advanced cancer often fail to gain weight with conventional nutritional support. This suboptimal response might be explained, in part, by an increased metabolic response to feeding. It has been suggested that eicosapentaenoic acid (EPA) can modify beneficially the metabolic response to cancer. The aim of the present study was to examine the metabolic response to feeding in cancer and the effects of an EPA-enriched oral food supplement on this response. A total of 16 weight-losing, non-diabetic patients with unresectable pancreatic adenocarcinoma and six healthy, weight-stable controls were studied by indirect calorimetry in the fasting and fed states. Body composition was estimated by bioimpedence analysis. Cancer patients were then given a fish-oil-enriched nutritional supplement providing 2 g of EPA and 2550 kJ daily, and underwent repeat metabolic study after 3 weeks of such supplementation. At baseline, resting energy expenditure whether expressed per kg body weight, lean body mass or body cell mass was significantly greater in the cancer patients compared with controls. Fat oxidation was significantly higher in the fasting state in cancer patients [median 1.26 g:kg − 1 :min − 1 (interquartile range 0.95-1.38)] than in controls [0.76 g:kg − 1 :min − 1 (0.62-0.92) ; P 0.05]. Over the 4 h feeding period, changes in insulin and glucose concentrations in cancer patients suggested relative glucose intolerance. In response to oral meal feeding, the percentage change in the area under the curve of energy expenditure was significantly lower in the cancer patients [median 7.9 % (interquartile range 3.4-9.0)] than in controls [12.6 % (9.9-15.1) ; P 0.01]. After 3 weeks of the EPA-enriched supplement, the body weight of the cancer patients had increased and the energy expenditure in response to feeding had risen significantly [9.6 % (6.3-12.4)], such that it was no different from baseline healthy control values. Similarly, fasting fat oxidation fell to 1.02 g:kg − 1 :min − 1 (0.8-1.18), again no longer significantly different from baseline healthy control values. While weight-losing patients with advanced pancreatic cancer have an increased resting energy expenditure and increased fat oxidation, the energy cost of feeding is, in fact, reduced. Provision of a fish-oil-enriched nutritional supplement results in some normalization of the metabolic response in both the fasted and fed states, in association with an improvement in nutritional status.
A B S T R A C T
Weight-losing patients with advanced cancer often fail to gain weight with conventional nutritional support. This suboptimal response might be explained, in part, by an increased metabolic response to feeding. It has been suggested that eicosapentaenoic acid (EPA) can modify beneficially the metabolic response to cancer. The aim of the present study was to examine the metabolic response to feeding in cancer and the effects of an EPA-enriched oral food supplement on this response. A total of 16 weight-losing, non-diabetic patients with unresectable pancreatic adenocarcinoma and six healthy, weight-stable controls were studied by indirect calorimetry in the fasting and fed states. Body composition was estimated by bioimpedence analysis. Cancer patients were then given a fish-oil-enriched nutritional supplement providing 2 g of EPA and 2550 kJ daily, and underwent repeat metabolic study after 3 weeks of such supplementation. At baseline, resting energy expenditure whether expressed per kg body weight, lean body mass or body cell mass was significantly greater in the cancer patients compared with controls. Fat oxidation was significantly higher in the fasting state in cancer patients [median 1.26 g:kg − 1 :min − 1 (interquartile range 0.95-1.38)] than in controls [0.76 g:kg − 1 :min − 1 (0.62-0.92) ; P 0.05]. Over the 4 h feeding period, changes in insulin and glucose concentrations in cancer patients suggested relative glucose intolerance. In response to oral meal feeding, the percentage change in the area under the curve of energy expenditure was significantly lower in the cancer patients [median 7.9 % (interquartile range 3.4-9.0)] than in controls [12. 6 % (9.9-15.1) ; P 0.01]. After 3 weeks of the EPA-enriched supplement, the body weight of the cancer patients had increased and the energy expenditure in response to feeding had risen significantly [9.6 % (6.3-12.4)], such that it was no different from baseline healthy control values. Similarly, fasting fat oxidation fell to 1.02 g:kg − 1 :min − 1 (0.8-1.18), again no longer significantly different from baseline healthy control values. While weight-losing patients with advanced pancreatic cancer have an increased resting energy expenditure and increased fat oxidation, the energy cost of feeding is, in fact, reduced. Provision of a fish-oil-enriched nutritional supplement results in some normalization of the metabolic response in both the fasted and fed states, in association with an improvement in nutritional status.
INTRODUCTION
Weight loss is a major cause of morbidity and mortality in patients with advanced cancer [1, 2] . Cachectic cancer patients often have a reduced dietary intake. However, while it is possible to increase energy and protein intake by enteral or parenteral means, this seems to have little impact on patients ' progressive weight loss [3] [4] [5] [6] [7] . This has led to the suggestion that there is a partial metabolic block to the accretion of lean tissue in patients with cancer [3, 8] , which may be due to pro-inflammatory cytokines, alterations in the balance of neuroendocrine hormones, and specific, tumour-derived proteolytic and lipid-mobilizing factors [9] . It has been reported that weight-losing patients with advanced cancer may have an increased resting energy expenditure, particularly those with an acute-phase protein response [10, 11] . Such increased resting energy expenditure may be due to an increase in futile metabolic cycles, such as the Cori cycle [12] , or to mitochondrial uncoupling proteins which increase heat production and are stimulated in inflammatory models by mediators similar to those present in cancer [13] . However, another component of energy expenditure is that associated with the digestion of food, and to date there has been little attempt to study the metabolic response to feeding in cancer. An exaggerated response to feeding may, to some extent, explain the lack of an anabolic response by cancer patients to the provision of additional food.
It has been suggested that eicosapentaenoic acid (EPA), an nk3 polyunsaturated fatty derived from fish oil, and fish oil itself will down-regulate the production and action of a number of mediators of cachexia, such as interleukin-6 [14, 15] and proteolysis-inducing factor [16] . We have recently shown that a fish-oil-enriched nutritional supplement will reverse weight loss in cachectic cancer patients [17] . It is possible, therefore, that such a nutritional supplement containing EPA or fish oil may modulate the metabolic response to feeding, explaining the improved response to nutritional support.
The present study examined the metabolic response to feeding in cachectic cancer patients compared with healthy controls, and also determined the effect on the response to feeding of the administration of a nutritional supplement containing EPA for 3 weeks in advanced cancer patients.
METHODS

Subjects
A total of 16 patients with an unequivocal diagnosis of pancreatic cancer who were losing weight, but with no clinical evidence of ascites, peripheral oedema, diabetes mellitus or malabsorption, were examined at baseline and after 3 weeks of consumption of a fish-oil-enriched nutritional supplement. In addition, six weight-stable healthy individuals served as healthy controls and were studied on one occasion only without going on to receive the fish-oil-enriched supplement. None of the patients received chemotherapy or radiotherapy, and none had undergone surgery in the preceding 4 weeks. No patients had clinical or radiological evidence of infection, were jaundiced or severely anaemic, or were receiving steroids. The study was approved by the local ethical committee, and all subjects gave written informed consent.
Metabolic study protocol
The study protocol is presented in Figure 1 . Subjects attended at 8.00 hours on two consecutive days. On the first day, following an overnight fast, the subject rested in a supine position for at least 30 min and underwent indirect calorimetry using a ventilated hood technique (Deltatrac ; Datex, Helsinki, Finland) [10] . Measurements were made for at least 30 min. The measurements made in the last 20 min were averaged to calculate resting energy expenditure using the Weir equation [18] . A venous catheter was inserted into the subject's antecubital fossa and baseline blood samples were collected for assessment of insulin, cortisol and glucose. Insulin and cortisol concentrations were analysed by radioimmunoassay as described previously [19] .
Subjects were weighed on spring-balance scales (Seca) without shoes and wearing light clothing. Body composition was measured using a Xitron 4000B multiplefrequency bioelectrical impedence analyser (Xitron Technologies, San Diego, CA, U.S.A.). All assessments were made with the subject supine and with limbs apart. Electrodes were placed over the wrist and ankle joints and the metacarpal and metatarsal heads. Repeat measurements were performed using the same pair of limbs. Resistance was measured at 5 and 200 Hz. Values for total body water and extracellular water were derived using equations validated in a similar patient group [20] . Lean body mass was calculated from total body water, assuming that lean tissue contains 73 % water. Body cell mass was calculated from intracellular water (total body water minus extracellular water), assuming that cell mass contains 70 % water [21] .
Energy expenditure was measured by indirect calorimetry for 20 min at 40 min intervals over the subsequent 4 h. The second 10 min of each 20 min measurement period was used to calculate energy expenditure. Subjects underwent blood sampling for measurement of serum insulin and glucose every 60 min during this 4 h period.
On the second day, following an overnight fast, a venous catheter was again inserted into the antecubital fossa for blood sampling. Subjects received hourly meals (for 4 h) of a balanced whole protein liquid nutritional Metabolic response to feeding in cancer supplement (Fortisip ; Nutricia, Zoetermeer, Holland), each meal providing a one-twelfth of the subject's estimated energy requirement (measured resting energy expenditurei1.4) [22] . The meal provided 13 % of energy from protein, 48 % from carbohydrate and 39 % from fat, similar to a ' typical ' British diet. The subject continued to rest in the supine position during the feeding period. Energy expenditure was measured by indirect calorimetry over 20 min every 40 min, as on the previous day, and subjects underwent blood sampling for measurement of serum insulin and glucose every 30 min during the feeding period.
Patients collected their urine for the 24 h period prior to attendence. After emptying their bladders on arrival to provide a timed fasting sample, subjects provided a urine sample over the 4 h study period on each day to provide an estimate of urinary nitrogen excretion in the fed state. Nitrogen loss was determined by measurement of urinary nitrogen using a rapid combustion and thermal conductivity cell method (Leco FP-328, St. Joseph, MI, U.S.A.).
Substrate utilization was calculated from oxygen utilization and carbon dioxide production (provided by indirect calorimetry) and urinary nitrogen excretion, in the fasting (baseline) and fed (after 200 min of the feeding protocol) states, using the equations of Consolazio et al. [23] .
The daily dietary intake of subjects was measured based on the mean dietary intake recorded in a 3-day food diary calculated using CompEat 4 software (Nutrition Systems, London, U.K.).
Fish-oil-enriched nutritional supplement
After the baseline metabolic study, cancer patients were asked, in addition to their normal dietary intake, to consume a nutritional supplement enriched with fish oil provided by Ross Products Division, Abbott Laboratories, Columbus, OH, U.S.A. (providing 2550 kJ, 32.2 g of protein, 2.2 g of EPA and 0.96 g of docosahexaenoic acid per day) for 3 weeks. The composition of this product is shown in Table 1 . Compliance was assessed by a diary of consumption, by return of labels from empty cans and by plasma fatty acid analysis at baseline and after 3 weeks' consumption of the supplement. After the 3-week supplementation period, patients attended for repeat metabolic assessment.
Statistical analysis
Unless otherwise stated, data are presented as median (interquartile range). Data were tested for significance using the Mann-Whitney U test, Wilcoxon signed rank test or Chi-squared test as appropriate (Statview ; Abacus Concepts, Berkeley, CA, U.S.A.). A P value of 0.05 was taken to denote significance.
RESULTS
Subject characteristics are shown in Table 2 . Cancer patients were older than the controls, but groups were of equal sex distribution. Cancer patients were significantly lighter than controls, having lost around 18 % of their 
Baseline metabolic studies
Baseline fasting metabolic characteristics are shown in Table 3 . There was no difference in overall resting energy expenditure between the cancer and control groups. However, as the cancer patients were significantly lighter, energy expenditure expressed per kg body weight, lean body mass or body cell mass was significantly greater in cancer patients than in controls. The fasting serum insulin concentration was significantly lower in cancer patients than controls. There was no significant difference between fasting cortisol concentrations between the two groups. However, the cortisol\ insulin ratio was significantly higher in cancer patients. There was no difference in fasting glucose concentrations between the two groups.
In the fasting state there was little change in metabolic measurements over a 4 h period. The area under the curve of energy expenditure increased from baseline by 2.1 % (1.0-3.5) in cancer patients and by 1.1 % (0.7-1.3) in controls. The difference between these groups was, however, not statistically significant (P 0.05). There was a decline in insulin concentration, such that the area under the curve decreased from baseline (as the fasting period continued following an overnight fast) by 13.9 % (2.9-40.7) in cancer patients and by 27.1 % (20.2-33.0) in controls. Again there was no significant difference between the two groups.
The changes in serum insulin concentrations of the cancer and control subjects over the study feeding period are shown in Figure 2 . There was a prompt and substantial increase in insulin concentration in control subjects. Cancer patients had a slower increase in insulin concentration. Insulin concentrations were significantly lower in cancer patients than in control subjects at 0, 30, 60 and 90 min (P 0.05 ; Mann-Whitney U test). Thereafter there was no significant difference in insulin concentrations between cancer patients and controls. In absolute terms, the change in insulin concentration over the study period in cancer patients was about two-thirds of that in healthy controls, although this difference did not reach statistical significance [cancer patients, 2195 units\240 min (954-3823) ; controls, 3234 units\240 min (2948-5810)]. Due to the lower fasting insulin concentration in cancer patients, the percentage change in the area under the curve of insulin concentration from baseline was very similar in the two groups [cancer patients 256 % (114-371) ; control subjects, 216 % (163-261)].
The change in glucose concentrations of cancer and control subjects over the study feeding period are shown in Figure 3 . There was no change in glucose concentration in control subjects over the feeding period. Cancer patients exhibited an increase in glucose concentration over the feeding period and had a significantly greater area under the curve of glucose concentration [cancer patients, 30.7 % (24.4-48.9) ; control subjects, 3.4 % (k11.7 to 11.6) ; P 0.01].
The changes in energy expenditure of cancer and control subjects over the study feeding period are shown in Figure 4 . Both groups had a rise in energy expenditure with feeding. This increase was significantly greater in control subjects than in cancer patients [cancer patients, 7.9 % (3.4-9.0) ; control subjects, 12.6 % (9.9-15.1) ; P 0.01]. In absolute terms this difference was more marked [cancer patients, 58.6 kJ\200 min (25.9-78.7) ; control subjects, 105.4 kJ\200 min (90.0-138.5) ; P 0.01]. Metabolic response to feeding in cancer Substrate utilization rates are shown in Table 4 . Rates of protein oxidation were similar in both groups in the fasting state. There was a small and non-significant rise in Median and interquartile range are shown. Percentage changes in area under the curve were : cancer patients, 30.7 % (24.4-48.9) ; control subjects, 3.4 % (k11.7 to 11.6) ; P 0.01 (Mann-Whitney U test). Absolute changes were : cancer patients, 426 mmol/240 min (260-598) ; control subjects, 38 mmol/240 min (k156 to 140) ; P 0.005 (Mann-Whitney U test). Each feed provided onetwelfth of the estimated daily energy requirement for each subject.
protein oxidation with feeding in both cancer patients and controls. Carbohydrate oxidation doubled in controls on feeding and tripled in cancer patients, a statistically significant rise in both groups. Levels of Median and interquartile range are shown. BCM, body cell mass. Percentage changes in area under the curve were : cancer patients, 7.9 % (3.4-9.0) ; control subjects, 12.6 % (9.9-15.1) ; P 0.01 (Mann-Whitney U test). Absolute changes were : cancer patients, 58.6 kJ/200 min (25.9-78.7) ; control subjects, 105.4 kJ/200 min (90.0-138.5), P 0.005 Mann-Whitney U test. Each feed provided one-twelfth of the estimated daily energy requirement for each subject.
carbohydrate oxidation tended to be higher in controls than in cancer patients, but this difference was not statistically significant ( Figure 5 (Figure 6 ). This rate fell by 26 % in cancer patients (P l 0.001) and by 22 % in controls (not significant) on feeding. In the fed state the difference in fat oxidation rates between patients and controls was no longer significant. 
Effects of 3 weeks' consumption of a fishoil-enriched nutritional supplement
Prior to enrolment, cancer patients had a rate of weight loss of 2.9 kg\month (3.8-1.9). After 3 weeks of the fish-oil-enriched nutritional supplement, patients had a median weight gain of 1.0 kg (k0.25 to 1.75) (P 0.05 compared with baseline). Lean body mass increased by a median of 0.75 kg (0.1-1.6) (P 0.05), while fat mass remained unchanged [0.0 kg (k0.6 to 0.9) ; not significant]. Patients tolerated the supplement well, consuming a median of 1.9 cans\day (range 1.25-2.0). Changes in baseline fasting metabolic characteristics are shown in Table 3 . Overall resting energy expenditure did not change after the 3-week supplementation period. However, because of the weight gain observed, resting energy expenditure per kg body weight and per kg lean body mass both fell by a small but statistically significant amount (P 0.05).
Serum fasting insulin concentrations rose significantly (P 0.01) over the 3-week supplementation period and were no longer significantly different from those of controls measured during the baseline studies. Fasting serum concentrations of cortisol did not change after the supplementation period. However, there was a significant fall in the cortisol\insulin ratio (P 0.01). There was no change in the fasting glucose concentration. Values are shown for the weight-losing pancreatic cancer patients (n l 16) and healthy controls (n l 6) at baseline, and for the same cancer patient group after 3 weeks of fish-oil-enriched nutritional supplementation. Median values are shown. Proportion of fat oxidation in the fasting state : P 0.05 for patients compared with controls (Mann-Whitney U test). All other differences were not statistically significant.
The change in insulin concentration with feeding after the 3-week supplementation period is shown in Figure 7 . The pattern observed was similar to that before intervention, with significantly lower insulin concentrations than controls at 30, 60 and 90 min, but no difference in values thereafter (values for controls are taken from the baseline study). Absolute and percentage change from baseline were again not significantly different between patients and controls studied at baseline. The change in glucose concentration with feeding also was not significantly different after the 3-week supplementation period, with an increase of 31.8 % (23.7-43.9) being observed in the area under the curve from baseline.
The percentage change in the area under the curve of energy expenditure from baseline was 9.6 % (6.3-12.4) in cancer patients after the 3-week supplementation period (Figure 8 ). This was significantly greater than for the same subjects at baseline (P 0.05), and was no longer significantly different from that of healthy controls at baseline (P 0.05). The absolute change in energy expenditure also increased significantly in cancer patients, to 78.7 kJ\200 min (51.5-96.2) (P 0.05).
Changes in substrate utilization after 3 weeks' administration of the fish-oil-enriched nutritional supplement are shown in Table 4 . Rates of protein and carbohydrate oxidation each rose slightly in the fed and fasting states in cancer patients, becoming similar to values observed in control subjects at baseline. Fasting fat oxidation fell to 1.02 g:kg −" :min −" (0.8-1.18), which was no longer significantly different from baseline control values (P 0.05) (Figure 9 ). This rate fell promptly on feeding, as had been seen in control subjects. The median percentage substrate utilization is shown in Figure 10 . At baseline there was a significant difference in the fat oxidation rate in the fasting state between patients and controls ( Figure 10 ). However, after 3 weeks of fish-oil-enriched nutritional supplement consumption there were no significant differences between the percentage nutrient utilization of patients after supplementation and control subjects at baseline (Figure 10 ).
DISCUSSION
The present study has examined the metabolic state during fasting and in response to feeding in weight-losing patients with pancreatic cancer compared with healthy, weight-stable controls. In the fasting state, cancer patients had a lower serum insulin concentration, an elevated resting energy expenditure per unit weight and an increased rate of fat oxidation. In response to feeding, cancer patients exhibited relative glucose intolerance, but a reduction in the metabolic cost of feeding compared with controls.
The present study also demonstrated that the administration of a fish-oil-enriched nutritional supplement containing EPA for 3 weeks resulted in weight gain in this previously weight-losing group, an increase in fasting insulin concentration and a normalization of energy expenditure, with a fall in resting energy expenditure per unit weight and a rise in the apparent metabolic cost of feeding. Substrate utilization was also normalized.
Relative glucose intolerance has been noted in cancer patients for many years [24] . A blunted insulin secretory response to oral glucose administration in association with delayed clearance of glucose was reported in cachectic colorectal cancer patients, although fasting insulin concentrations did not differ between patients and controls in that study [25] . Another study of colorectal cancer patients suggested normal insulin sensitivity but impaired insulin responsiveness, implying a post-receptor defect in insulin action [26] . In the present study there was a relative blunting of the insulin response in the cancer patients, with lower insulin concentrations over the early part of the feeding period. Over the whole time course there was, however, no statistically significant difference in the absolute or percentage change in insulin concentration between cancer patients and controls. This may reflect relatively small patient numbers combined with substantial inter-individual variation. However, the present results suggest a delay in the insulin response in the cancer patients rather than a difference in its overall magnitude. It has been suggested that islet amyloid polypeptide (amylin) produced by normal pancreatic tissue in patients with pancreatic cancer may contribute to insulin resistance [27, 28] .
Although non-cancer-bearing subjects who have lost weight have been reported to have lowered resting energy expenditure in the fasted state, there is little evidence in normal subjects of energy conservation through a change in the energy cost of feeding [29, 30] . We hypothesized that, in cancer patients, in whom there appears to be an increase in resting energy expenditure and a failure to gain weight despite an increase in food intake [4, 7] , there may be an increased energy cost of feeding. However, in the present study we found that the change in energy expenditure with feeding was actually smaller than that seen in controls. Moreover, the size of the feeding stimulus provided was based on resting energy expenditure, and this was relatively greater in cancer patients. Thus the observed reduction in the metabolic response to oral feeding in the cancer paients was even greater in relation to the quantity of food provided.
It has been shown previously that non-weight-losing cancer patients are similar to healthy controls in their energy response to oral feeding [31] . Intravenous nutrition has been shown to produce a similar metabolic response in malnourished cancer patients and malnourished controls [32] . Although no normally nourished control group was examined in the latter study, it was suggested that, while cachectic cancer patients may exhibit metabolic changes in the fasting state, these patients were able to conserve energy normally upon intravenous feeding. The present study suggests that this is also true with oral feeding.
Due to a lack of pancreatic lipase, pancreatic cancer patients frequently have problems with malabsorption, particularly of fat [33] . None of the subjects in the present study had symptomatic malabsorption, but clearly, if there was a reduction in the proportion of food absorbed or in the rate of absorption, this may have accounted for some of the observed differences. However, the prompt rise in blood glucose concentration and the rise in insulin concentration of equal proportion compared with controls does not suggest a substantial difference in absorption in the cancer patients. Moreover, the cancer patients were able to gain weight over the 3-week study period, again suggesting reasonable absorption.
As in the present study, an increase in the proportion of fat oxidation has been observed previously in fasting patients with gastrointestinal cancer when compared with controls [34, 35] . A corresponding significant decrease in carbohydrate oxidation has also been reported in weight-losing cancer patients [34] . In the latter study the changes were more pronounced in patients with more advanced disease. Although there was a trend towards a decrease in carbohydrate oxidation in the present study, this was not statistically significant. The equations used for the calculation of substrate utilization are not ideal for subjects in the fed state [36] . Within these limitations, the cancer patients in the present study demonstrated a marked increase in carbohydrate oxidation with feeding. Such a change in substrate oxidation is observed in healthy individuals and has been documented in other groups of cancer patients [31, 32] . Thus it appears that, in the fasting state, weight-losing cancer patients preferentially oxidize fat despite their reduced percentage fat mass, perhaps because of depletion of glycogen stores. In the fed state a switch to normal substrate oxidation patterns is seen.
The administration of a nutritional supplement containing EPA to patients with pancreatic cancer resulted in an increase in weight, an increase in fasting insulin concentration, a decrease in resting energy expenditure and a normalization of the metabolic cost of feeding and substrate utilization. It has been shown previously that EPA will lower production of pro-inflammatory cytokines in cancer patients [15] . These cytokines increase energy expenditure, reduce insulin levels, increase cortisol concentrations, induce insulin resistance, stimulate the acute-phase response and cause protein and fat breakdown [37] . Modulation of these and other factors by the EPA-containing supplement may explain the relative normalization of the metabolic state observed. EPA also modulates the activity of other factors implicated in weight loss in cancer patients, such as proteolysis-inducing factor [16] , and the present study has also shown changes in the neuroendocrine state, with a rise in the fasting insulin concentration. The changes observed cannot be ascribed to EPA alone, as the relative roles of other components of the fish-oil-enriched supplement, including docosahexaenoic acid, are yet to be determined.
Fish oil supplementation has been suggested to adversely affect glucose metabolism in otherwise well patients with type II (non-insulin-dependent) diabetes mellitus [38, 39] . However, a study of patients with hypertension given 4 g of fish oil or placebo daily for 16 weeks specifically addressed this issue, and showed no change in response to glucose tolerance testing, insulin release or insulin sensitivity in those subjects given fish oil, and no differences between groups [40] . The present study did not demonstrate any adverse effect on glucose tolerance caused by administration of the fish-oilenriched supplement.
The apparent improvement in the nutritional state of the cancer patients in the present study may have contributed to the metabolic changes observed over the 3-week study period. The patients' energy intake increased by around 1670 kJ (400 kcal). Previous studies using conventional nutritional supplements in cancer patients in which a similar increment in protein and energy intake was achieved failed to produce nutritional benefit [4, 7] . Thus it is conceivable that it was the EPA component of the supplement that resulted in modulation of the weight-losing state and allowed the protein and energy supplied to be used with more benefit. To compare the metabolic changes associated with the fish-oil-enriched supplement, we performed a paired comparison with data from subjects prior to consumption of the supplement and a comparison with the data for the patients who were only studied at baseline and who did not receive the fish-oil-enriched supplement. The ideal study design would have been to also observe the effects of the supplement on control subjects. However, the present study design allowed us to assess whether the supplement restored metabolic function towards that observed in health.
The present study suggests that the energy cost of feeding is not elevated in cancer patients, and therefore does not contribute to the apparent block to the accretion of lean tissue in cachectic cancer patients. The increase in the cost of feeding after EPA supplementation in association with weight gain implies a normalization of the metabolic state, with less need to conserve energy in the presence of weight gain. Our observation that the metabolic cost of feeding is lower in cancer patients than in control subjects suggests that this component at least of total energy expenditure has adapted to the weightlosing state. Similar observations have been made concerning the fall in energy expenditure associated with activity that is observed in advanced cancer patients [41] . The results of the present study suggest that an EPA-enriched nutritional supplement can reduce the previously elevated resting component of energy expenditure in cancer patients. Whether this trend back towards normality would allow a modest increase in activity, and might therefore impact on patients' quality of life, is the subject of ongoing studies.
